Use of robotics added almost 40% to the average cost of a radical prostatectomy compared with radical retropubic prostatectomy (RRP), analysis of a statewide database showed.
Use of robotics added almost 40% to the average cost of a radical prostatectomy compared with radical retropubic prostatectomy (RRP), analysis of a statewide database showed.
The cost of a robot-assisted laparoscopic radical prostatectomy (RALRP) averaged $14,000 versus $10,100 for RRP. Higher charges for operating room time and supplies for the robotic procedure accounted for most of the difference.
A similar differential existed among high-volume institutions and high-volume surgeons. However, higher-volume centers and surgeons were associated with a lower cost for RRP (p
"No definitive conclusions can be drawn from this study, but the findings are provocative," said first author Elias S. Hyams, MD, of Johns Hopkins University in Baltimore. "The study confirms a cost differential that has been reported by others.
"Even though we, as urologic surgeons, tend to focus on caring for the individual patient, I think we do need to step back and take more of a macroscopic look at the costs and see whether we can identify ways to make robotic surgery more cost-effective," added Dr. Hyams, who worked on the study with Brian R. Matlaga, MD, and colleagues.
Robot-assisted surgery has faced increasing scrutiny as data have emerged to suggest that the technology is associated with higher costs compared with conventional surgery. To examine the issue, Dr. Hyams and colleagues reviewed records from the Maryland Health Service Cost Review Commission, which requires the state’s acute care hospitals to report encounter-level and discharge data.
The study encompassed 2008 to 2011, during which time 1,499 men underwent RALRP and 2,565 underwent RRP. The $3,900 cost differential was statistically significant (pp
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.